DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Depressive Disorder, Major

Intervention: sertraline/[S,S]-reboxetine (Drug); sertraline/[S,S]-reboxetine (Drug); sertraline (Drug); sertraline (Drug); sertraline/[S,S]-reboxetine (Drug); Placebo (Drug); sertraline/[S,S]-reboxetine (Drug); [S,S]-reboxetine monotherapy (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.

Clinical Details

Official title: Sertraline/[S,S]-Reboxetine Combination Versus Sertraline And [S,S]-Reboxetine Monotherapy In Major Depressive Disorder (MDD) In A Double-Blind, Placebo-Controlled, Eight Week Study.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: The change from Baseline up to Week 8 (Visit 9) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score as measured by a mixed concentration, suicidal ideation and restlessness.

Secondary outcome:

Change from Baseline in HAM-D (17-item) total score

Change from Baseline in the Hamilton Anxiety Rating Scale (HAM-A) and Apathy Evaluation Scale (AES)

The frequency and severity of treatment-emergent adverse events, ECG changes, laboratory and vital signs changes by treatment group using descriptive statistics.

Change from Baseline in MADRS total score

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects must fulfill the criteria for MDD without psychotic features as defined by

DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview for DSM-IV Axis I Disorder-Clinical Version (SCID-I) plus the MDD Specifiers included in the Research Version of SCID-I.

- HAM-D (17-item) ≥ 22 at Screening (Visit 1) and > 20 at Baseline (Visit 2).

- Minimum CGI-S ≥ 4 at Screening (Visit 1) and at Baseline (Visit 2).

Exclusion Criteria:

- Known failure to satisfactory respond after adequate dose and duration (12 weeks) of

treatment with clomipramine and one SSRI, or with two or more SSRIs.

- Subjects with > 20% HAM-D (17-item) improvement (decrease) from Screening (Visit 1)

at Baseline (Visit 2).

- Subjects with uncorrected hypothyroidism or hyperthyroidism.

Locations and Contacts

Pfizer Investigational Site, Pärnu 80012, Estonia

Pfizer Investigational Site, Tallinn 10614, Estonia

Pfizer Investigational Site, Tartu 51008, Estonia

Pfizer Investigational Site, Kazan 420012, Russian Federation

Pfizer Investigational Site, Moscow 107076, Russian Federation

Pfizer Investigational Site, Moscow 115522, Russian Federation

Pfizer Investigational Site, Moscow 119034, Russian Federation

Pfizer Investigational Site, Moscow 127473, Russian Federation

Pfizer Investigational Site, Moscow, Russian Federation

Pfizer Investigational Site, Rostov On Don 344010, Russian Federation

Pfizer Investigational Site, Smolensk 214019, Russian Federation

Pfizer Investigational Site, St Petersburg 190121, Russian Federation

Pfizer Investigational Site, St. Petersburg 192019, Russian Federation

Pfizer Investigational Site, St. Petersburg 193167, Russian Federation

Pfizer Investigational Site, St. Petersburg 194214, Russian Federation

Pfizer Investigational Site, Tomsk 634014, Russian Federation

Pfizer Investigational Site, Moscow, Russia, Russian Federation

Pfizer Investigational Site, St. Petersburg, Russia 192019, Russian Federation

Pfizer Investigational Site, Viljandi, Viljandi mk. 71024, Estonia

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: June 2004
Last updated: April 3, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017